Figure 4From: Innate immune response after acute myocardial infarction and pharmacomodulatory action of tacrolimus in reducing infarct size and preserving myocardial integrityImmunohistochemical (IHC) staining of the innate inflammatory cells in infarct area (IA) and peri-IA at day 21 after AMI induction. Upper panel: A to E) Illustration of IHC staining of CD14+ cells (yellow arrows) in infarct area (IA) and peri-IA of left ventricle. F) Quantification of number of CD14+ cells. At IA, * vs. other bars with different symbols, p<0.0001. At peri-IA, * vs. other bars with different symbols, p<0.01. (n=6 for each group). Lower panel: A to E) Illustration of IHC staining of inducible nitric oxide synthase (iNOS) + cells (yellow arrows) in IA and peri-IA of left ventricle. F) Quantification of iNOS+ cells. At IA, * vs. other bars with different symbols, p<0.0001. At peri-IA, * vs. other bars with different symbols, p<0.001. All statistical analyses using one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡ or *, §, ¶) indicate significance (at 0.05 level). HPF = high-power field; AMI = acute myocardial infarction; Tac = tacrolimus. (n=6 for each group).Back to article page